Tuesday, February 11, 2025 7:50:01 AM
FYI I spoke with NICE in September and was told:
Thank you for your email regarding whether the company evidence submission will be published on our website.
A copy of the company evidence submission is made available on our website prior to publication of technology appraisal guidance. In line with our usual processes, confidential information would be redacted from the document before publication.
The evidence submission forms part of the committee papers which we make available on our website at the time that we publish either draft guidance or final draft guidance. Committee papers for this appraisal would be published on the project documents page.
Draft guidance will only be produced if the recommendations from the evaluation committee do not recommend use of the technology or limit the use of the technology beyond the specifications in the marketing authorisation. This outlined in the overview.
I hope this information is helpful.
Kind regards
Thank you for your email regarding whether the company evidence submission will be published on our website.
A copy of the company evidence submission is made available on our website prior to publication of technology appraisal guidance. In line with our usual processes, confidential information would be redacted from the document before publication.
The evidence submission forms part of the committee papers which we make available on our website at the time that we publish either draft guidance or final draft guidance. Committee papers for this appraisal would be published on the project documents page.
Draft guidance will only be produced if the recommendations from the evaluation committee do not recommend use of the technology or limit the use of the technology beyond the specifications in the marketing authorisation. This outlined in the overview.
I hope this information is helpful.
Kind regards
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
